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Summary
Aminoacyl-tRNA synthetases prevent mistranslation,
or genetic code ambiguity, through specialized editing
reactions. Mutations that disrupt editing in bacteria
adversely affect cell growth and viability, and recent
work in the mouse supports the idea that translational
errors caused by an editing defect lead to a neurologi-
cal disease-like phenotype. To further investigate the
connection of mistranslation to cell pathology, we in-
troduced an inducible transgene expressing an edit-
ing-deficient valyl-tRNA synthetase into mammalian
cells. Introducing mistranslation precipitated a dis-
ruption of cell morphology and membrane blebbing,
accompanied by activation of caspase-3, consistent
with an apoptotic response. Addition of a noncanoni-
cal amino acid that is misactivated, but not cleared,
by the editing-defective enzyme exacerbated these ef-
fects. A special ambiguity-detecting sensor provided
direct readout of mistranslation in vivo, supporting
the possibility that decreased translational fidelity
could be associated with disease.
Introduction
Connections between specific human diseases and
aminoacyl-tRNA synthetases (AARSs) illustrate the
emerging awareness of the importance of these en-
zymes in disease pathology [1, 2]. Although the mecha-
nism of disease causation is not known, we hypothesize
that defects in activities idiosyncratically associated
with specific synthetases, such as editing, could be re-
sponsible for pathological mutations. In a related vein,
potential links between faulty translation and disease
have been reported for specific translation factors. For
example, levels of the translation initiation factor
eIF-4E are elevated in human cancers and are linked to
conversion of cells into malignant states in culture [3–
5]. In one study, NIH/3T3 cells exhibited a transformed
phenotype after overexpression of eIF-4E. Tumors de-
veloped when the transformed cell lines were injected
into nude mice. In another investigation, profound neu-
romuscular problems were observed in mice that carry
a deleterious mutation in translation elongation factor
eEF1A2 [6–8]. Recently, protein synthesis was again
highlighted in the human neurodegenerative disease
VWM/CACH (vanishing white matter/childhood ataxia
*Correspondence: schimmel@scripps.eduwith central hypomyelination). This disease is con-
nected to mutations in translation factor eIF-2B [9, 10].
These examples illustrate that maintaining control,
and possibly fidelity, in translation may be far more sen-
sitive and subtle than previously thought. With that in
mind, we sought to determine whether inducing mis-
translation via mutation of a component of the transla-
tion apparatus, i.e., an aminoacyl-tRNA synthetase,
could be connected to an apparent phenotype in mam-
malian cells. Many tRNA synthetases have editing activ-
ities to correct errors of aminoacylation and prevent
mistranslation, or genetic code ambiguity [11–13]. At
least in bacterial cells, these activities are critical for op-
timal cell growth and, under some circumstances, cell
viability [14, 15]. Thus, disruption of tRNA synthetase
editing functions may also have broad consequences
in mammalian cells. The significance of the editing func-
tion traces back to the highly accurate genetic code al-
gorithm relating each amino acid to specific nucleotide
triplets found in messenger RNAs (mRNAs). This algo-
rithm is established in aminoacylation reactions cata-
lyzed by AARSs, in which each amino acid is linked to
the 20 or 30 OH of the cognate tRNA that bears the anti-
codon triplet of the code that corresponds to the at-
tached amino acid [16–18]. To maintain high accuracy
levels [13, 19, 20], certain AARSs that are forced to dis-
criminate between sterically similar amino acids have
a second active site that clears, or edits, incorrectly
charged amino acids [21–24]. If a mutation affects the
editing function of one of these enzymes, production
of mischarged tRNAs results in misincorporation of
amino acids that can, in principle, create pools of statis-
tical, heterogeneous proteins [25–27].
Recently, mice harboring a single missense mutation
in the editing domain of alanyl-tRNA synthetase (AlaRS)
were shown to exhibit severe ataxia accompanied by
degeneration of Purkinje cells in the brain [28]. The mu-
tation in murine AlaRS produced a partial defect in the
ability of the enzyme to clear mischarged Ser-tRNAAla
in vitro. Although the editing defect was only partial,
a strong phenotype was seen in the mouse. In particular,
ataxia and Purkinje cell degeneration were accompa-
nied by the upregulation of cytoplasmic protein chaper-
ones and induction of the unfolded protein response.
Here, we report results of a laboratory-based system
to directly study mistranslation within mammalian cells
that harbor an editing-deficient tRNA synthetase. We
chose a different enzyme that has a potent activity for
preventing mistranslation, ValRS. This choice enabled
us to investigate whether the kind of effects seen in
mouse were idiosyncratic to AlaRS or more general.
Also, by working with a mammalian cell system in cul-
ture, we could more closely control the production of
the editing-defective enzyme and set up a specialized
system to give a direct readout of mistranslation. The re-
sults obtained support the hypothesis that pathological
states can arise from mistranslation in mammalian cells,
caused by a single missense mutation in the editing do-
main of a tRNA synthetase and, in addition, that such
mutations can dominate over the wild-type allele.
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1092Figure 1. Modeling of a Mutated Residue
within the Editing Domain of M. musculus
ValRS
(A) Alignment of residues in the editing site
of ValRS from Homosapiens (Hs), Mus mus-
culus (Mu), Saccharomyces cerevisiae (Sc),
Escherichia coli (Ec), and Thermus thermo-
philus (Tt). Highly conserved residues are
shaded in dark gray; light-gray shading indi-
cates isosteric residues at conserved sites.
The arrow indicates the location of mutated
T in ValRS.
(B) Model of the editing domain of M. muscu-
lus ValRS created by 3D-PSSM based on the
structure of T. thermophilus ValRS highlight-
ing the location of T535. Residues are
indicated with M. musculus numbering.
Inset: T535 proximity to the bound Thr-AMS
analog.
(C) Modeling the T535P substitution onto the
editing domain of M. musculus ValRS. Inset:
Proximity change of T535P to the bound
Thr-AMS analog.Moreover, the severity of the cellular response appears
to be correlated with the degree of mistranslation that is
induced.
Results
Structural Implications for Creating Editing-
Deficient ValRS
The editing reaction of ValRS occurs at a distinct second
active site located in an insertion, the connective poly-
peptide 1 (CP1), that is conserved throughout archaea,
bacteria, and eukaryotes [29–31]. Point mutations in
CP1 of Escherichia coli ValRS render the enzyme in-
capable of efficient hydrolysis of mischarged tRNAs,
such as Thr-tRNAVal, which are then released for
mRNA decoding [15, 25]. At the same time, presumably
because the site for editing is distal to the active site for
aminoacylation, these editing-defective mutants are
fully competent for aminoacylation. In the presence of
a DvalS null background in E. coli, each tested editing-
defective mutant ValRS adversely affected bacterial
cell viability when cells were grown in the presence of el-
evated amounts of a noncognate amino acid that is mis-
activated by ValRS (i.e., Thr, L-a-aminobutyric acid [a-
Abu]). The magnitude of the editing defect measured
in vitro directly correlated with the degree of sensitivity
to noncognate amino acid addition that was observed
in vivo.
T222P E. coli ValRS was the most editing defective of
the previously studied enzymes. Significantly, T222 in E.
coli ValRS is highly conserved through evolution
(Figure 1A). (Of the available ValRS sequences, only
a few bacterial species, including Thermus thermophilus
and some species of Deinococcus, have replaced this
highly conserved T with the isosteric V. Interestingly, T
also appears at this position in other class I editing-pro-
ficient aminoacyl-tRNA synthetases [IleRS and LeuRS]
that contain the CP1 insertion [32, 33].) Recently, the
structure of the T. thermophilus ValRS editing domain
complexed with a Thr-AMP analog (N-[L-threonyl]sulfa-
moyl)adenosine was solved [34]. This structure providedthe opportunity to rationalize the severe phenotype
of the T222P substitution in E. coli ValRS, and to visual-
ize the corresponding substitution in a mammalian
ValRS (T535P Mus musculus ValRS), indicating its po-
tential effects on hydrolytic editing. Using the structure
of the T. thermophilus CP1 insertion as a scaffold,
a model of the M. musculus ValRS [35] active site for ed-
iting was generated by homology modeling by using the
program 3D-PSSM (three-dimensional position-specific
scoring matrix) [36, 37]. Side chains were constructed
with SCWRL [38]. A PSSM E-value of 0.00339 was as-
signed to the model and indicated >95% confidence in
the prediction. In this model, a T is placed at the position
corresponding to T535 in M. musculus ValRS, replacing
V214 in T. thermophilus ValRS (Figure 1B). In this model,
the residue corresponding to T535 is close to the bound
Thr-AMS and helps to form the binding pocket for the
misactivated adenylate or the threonyl moiety of Thr-
tRNAVal. When a P replaces T535, assuming no struc-
tural rearrangement, the misactivated substrate is partly
occluded (Figure 1C). (More likely, the introduced P
would produce a significant distortion of the binding
pocket.) This analysis provided a structural rationale
for the potency of the previously studied T222P substi-
tution of E. coli ValRS and supported the idea that a
similar substitution in M. musculus ValRS would be
deleterious to editing.
Initial Characterization of T535P M. musculus ValRS
Wild-type and T535P M. musculus ValRS were overex-
pressed in E. coli, isolated, and assayed for aminoacyla-
tion activity. Both proteins were functional for amino-
acylation (Figure 2A) of bulk mammalian tRNA isolated
from bovine liver. That the aminoacylation activities of
these enzymes were similar shows that introduction of
the T535P mutation introduced no large-scale structural
changes that would interfere with the active site for ami-
noacylation. This result is consistent with prior work with
the E. coli ortholog and further established that the
two active sites, separated by w30 A˚, are functionally
independent.
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hydrolyze Thr-tRNAVal was investigated (Figure 2B).
For this purpose, the necessary large amounts of pure
[3H]-Thr-tRNAVal were generated by using E. coli
T222P ValRS to mischarge endogenous purified E. coli
tRNAVal (for reasons of technical constraints and conve-
nience, mammalian Thr-tRNAVal was not prepared).
While E. coli tRNAVal is a poor substrate for aminoacyla-
tion by M. musculus ValRS, the mammalian enzyme can
still distinguish Thr from Val in the context of E. coli
tRNAVal and can hydrolyze mischarged Thr-tRNAVal, as
was observed for the wild-type enzyme here. (A similar
lack of preference in tRNA selection by the hydrolytic
editing site has also been observed for PheRS from Sac-
charomyces cerevisiae. In this case, the cytoplasmic
PheRS cannot aminoacylate mitochondrial tRNAPhe,
yet it readily deacylates mischarged mitochondrial
Tyr-tRNAPhe in trans [39].) In contrast, T535P ValRS
was severely compromised for clearing Thr-tRNAVal.
Thus, as seen for the E. coli enzyme, the T/ P substi-
tution at the analogous position in ValRS greatly re-
duced its hydrolytic editing activity.
Figure 2. T535P ValRS Is Deficient in Editing, but Not Aminoacylation
(A and B) (A) Aminoacylation of tRNA with valine and (B) deacyla-
tion of misacylated [3H]-Thr-tRNAVal by WT and T535P ValRS. Re-
sults are representative of means from three independent experi-
ments.Expression of Wild-Type and Editing-Defective
ValRS in Mammalian Cells
To test the effects of a ValRS editing deficiency in vivo,
an inducible transgene of both wild-type and T535P
ValRS was constructed. Mammalian ValRS, like other
AARSs of higher eukaryotes, has additional domains
that are appended to the highly conserved core enzyme
that is the ortholog of prokaryotic ValRSs [40, 41]
(the core itself hasw32 % sequence similarity between
E. coli and M. musculus ValRS). These additional do-
mains are dispensable (for aminoacylation) and are con-
tained within a 295 amino acid polypeptide fused to the
N-terminal side of the core enzyme [42–46]. Treatment
with elastase selectively cleaves w250 amino acids
from the N-terminal side of full-length human ValRS
[44, 46], suggesting that, under some circumstances,
a truncated form may occur naturally in mammalian
cells. The most N-terminal of these appended domains
is unique to ValRSs of higher eukaryotes and is required
to facilitate the formation of a 5 subunit 700 kDa complex
between ValRS and elongation factor 1H [44, 47, 48]. In
addition to aminoacylation activity, this complex
functions in translation to sustain mRNA-dependent
polypeptide synthesis in the presence of EF-2 and
mRNA-dependent binding of charged tRNA to ribo-
somes. Because cells specifically expressing T535P
(but not wild-type) ValRS were unstable, the transgene
was constructed to encode a protein in which residues
1–295 were removed from the N terminus to create
ValRSD (a transgene similar to that used by Park et al.
to overexpress human ValRS in HEK293 cells [49]),
thereby allowing us to generate mischarged tRNAVal in
mammalian cells. We speculate that, with full-length
T535P ValRS, Thr-tRNAVal is more efficiently transferred
to the EF-1H complex and the ribosome than is the case
with the T535P ValRSD. This increase in efficiency would
result in more mistranslation and greater toxicity.
Constructs encoding wild-type and T535P mutant
ValRSD were transfected into NIH/3T3 mouse fibroblast
cells and, after induction for 24 hr, yielded soluble pro-
tein. Stably transfected cell lines capable of expressing
each of the constructs were generated, with both trans-
gene constructs yielding a single cell line. Production of
recombinant ValRSD in these cell lines was dependent
on induction by mifepristone (MFP), and there was no
basal expression detectable (by western blot) in the ab-
sence of MFP (Figure 3A). The cell lines encoding wild-
type and T535P ValRSD expressed protein at similar
levels, with slightly more ValRSD seemingly produced
in the wild-type cell line at the same concentration of
the MFP inducer.
Introduction of an Editing-Deficient ValRSD
Transgene Disrupts Mammalian Cell Morphology
in a Manner Exacerbated by a-Abu
Prolonged induction of the stably transfected NIH/3T3
cell line encoding T535P ValRSD led to a profound dom-
inant-negative transformation in cell morphology (Fig-
ure 3B). After 24–48 hr of induction, many cells were
no longer attached to the culture flask and instead
were found floating in the media. While the cells that re-
main attached appear to retain contact inhibition, and
grow as a monolayer, the gapped regions seen between
clusters of cells remain prominent over time so that
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of ValRSD Transgenes
Stably transfected NIH/3T3 cells treated with
MFP to induce expression of the WT or
T535P ValRSD transgene.
(A) Cell lysates analyzed for transgene
expression by immunoblotting with anti-V5-
HRP antibody. No basal expression was
observed (2MFP).
(B) Phenotypic response of uninduced
(2MFP) or induced (+MFP) WT and T535P
ValRSD cells grown for 48 hr.
(C) Effects exacerbated in cells expressing
T535P ValRSD when cells are grown in
a-Abu (100 mM) for 48 hr. White arrows indi-
cate incidences of membrane blebbing,
which is indicative of an apoptotic-like re-
sponse in cells expressing T535P ValRSD.
(D) Activation of caspase-3 was observed in
cells expressing T535P ValRSD, as measured
by cleavage of a caspase-3-specific fluoro-
genic substrate (Ac-DEVD-AMC) when incu-
bated with cell lysates. Increased levels of
caspase-3 activation were observed when
cells expressing T535P ValRSD were grown
in the presence of a-Abu (100 mM) for 24 hr.
The fractional difference in fluorescence is
relative to assays of uninduced cell lysates.
Results are representative of six indepen-
dent experiments presented as means 6
SEM.
(E) Immunoblot of lysates (50 mg) from unin-
duced (2MFP) or induced (+MFP) WT and
T535P ValRSD cells with the anti-polyubiqui-
tin monoclonal antibody.a confluent monolayer cannot be achieved. Many cells
were observed to exhibit altered morphologies charac-
terized by cell contraction and membrane blebbing (as
indicated by white arrows). These morphologies are
hallmarks of apoptosis. In contrast, induction of the sta-
ble cell line encoding wild-type ValRSD caused only
a subtle cell-shape change (Figure 3B). Similar pheno-
typic changes were observed upon induction of full-
length wild-type ValRS in a generated stable cell line,
showing that the phenotypic effect cannot be attributed
to overexpression of truncated ValRS.
To investigate further whether phenotypic differences
in cells expressing wild-type versus T535P ValRSD were
caused by genetic code ambiguity introduced by errors
of aminoacylation, expression in stably transfected NIH/
3T3 cell lines was induced in media supplemented with
the natural metabolite a-Abu (concentrations ranged
from low micromolar to millimolar). ValRS activatesa-Abu (KM elevatedw100-fold in relation to Val) to pro-
duce a-Abu-tRNAVal [50] (Figure 3C). Uninduced cells
were not visibly affected by the addition of a-Abu (up
to 2 mM). As mentioned above, cells expressing wild-
type ValRS showed a subtle phenotypic change upon in-
duction. However, no further changes were observed
when cells were incubated in media supplemented
with a-Abu, up to concentrations of 2 mM. In contrast,
the phenotype observed upon induction of T535P
ValRSD was exacerbated dramatically by the introduc-
tion of a-Abu to the media (Figure 3C). The number of
cells remaining attached to the tissue culture dish corre-
lated inversely with the concentration of a-Abu, with the
least amount of viable cells present at the highest a-Abu
concentrations. Additionally, more numerous inci-
dences of membrane blebbing were observed when
cells were treated with a-Abu (white arrows). This strik-
ing phenotype demonstrates that, in mammalian cells,
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tion in a specific tRNA synthetase severely affects cell
morphology and viability.
Prolonged endoplasmic reticulum stress induced by
accumulation of unfolded/misfolded proteins leads to
cell death via apoptosis. This process is highlighted by
an increase in polyubiquitinylation of the unfolded
protein substrates, targeting them for proteosomal
degradation. To test whether the apoptotic-like re-
sponse observed upon induction of T535P ValRSD could
be linked to ER stress, cell lysates were immunoblotted
with an antibody to specifically detect polyubiquitiny-
lated proteins. Cells expressing T535P ValRSD show
a marked increase in polyubiquitinylation compared to
uninduced cells and cells expressing wild-type ValRSD
(Figure 3E), thus suggesting that an accumulation of
misfolded/unfolded proteins may be linked to the apo-
ptotic-like response.
Expression of Editing-Deficient ValRS Induces
a Caspase-3-Mediated Apoptotic Response
The execution phase of programmed cell death or apo-
ptosis is characterized by marked changes in cell mor-
phology. One of the most notable of these phenotypic
transformations is the effect of membrane blebbing
that we observed in cells after induction of T535P
ValRSD. To explore the link between expression of
T535P ValRSD and apoptosis, the activation of cas-
pase-3 (a marker used to identify cells undergoing
apoptosis) was investigated. Produced as an inactive
zymogen, caspase-3 undergoes proteolytic activation
during apoptosis that, in turn, converts the enzyme to
a functional cysteine protease [51]. Cleavage by acti-
vated caspase-3 was monitored by measuring release
of a linked fluorophore upon cleavage of a caspase-3-
specific peptide (Ac-DEVD-AMC).
A significant increase in fluorescence resulting from
activation of caspase-3 was detected when the fluoro-
genic peptide was incubated with lysates from induced
cells expressing T535P ValRSD compared with lysates
from uninduced cells (Figure 3D). Mirroring the trend
observed in morphology transformation, when cells ex-
pressing T535P ValRSD were treated with a-Abu, the
levels of activated caspase-3 increased considerably
over those found in induced, untreated cells. In contrast,
no significant activation of caspase-3 was observed in
induced cells expressing wild-type ValRSD (Figure 3D,
inset) compared to uninduced cells, regardless of the
presence or absence of a-Abu. Also, when the T535P
ValRSD cell line was not induced, but was treated with
a-Abu, only a small increase in activated caspase-3
was observed over untreated cells. These results show
that genetic code ambiguity in a mammalian cell,
induced by the prolonged expression of an editing-
deficient ValRSD, results in the initiation of an apoptotic
response that involves caspase-3 activation. Encourag-
ing increased misincorporation by treatment with a-Abu
(a noncognate amino acid that can be misactivated by
ValRS) exacerbated this response.
Construction of a Mistranslation-Detecting Sensor
To demonstrate genetic code ambiguity in cells ex-
pressing the editing-deficient T535P ValRSD, we de-
signed a method to directly monitor the misincorpora-tion of T at V codons. This method was based on the
enhanced form of green fluorescent protein (EGFP)
from the Pacific Northwest jellyfish Aequorea victoria.
EGFP has a T at position 65 of its consensus sequence
(T-Y-G) that is essential for enhanced fluorescence
activity [52–54]. Changes in fluorescence occur upon
introduction of substitutions within this consensus se-
quence. (Substitution of T for wild-type S65 accounts
for the enhanced fluorescence and red-shifted excita-
tion maxima of EGFP [55].) We hypothesized that intro-
duction of V65 would alter the fluorescent profile of
GFP, allowing detection of misincorporation of T at the
position 65 V codon (Figure 4A).
To test this concept, a gene encoding T65V EGFP was
transiently transfected into NIH/3T3 cells in culture. In
contrast to cells expressing wild-type EGFP, after 48 hr
those expressing T65V exhibited, at most, a minimal fluo-
rescent signal (Figures 4B and 4C). Expression of T65V
EGFP was verified by immunodetection with a labeled an-
tibody to GFP (Alexa 568-GFP). This result showed that
the lack of fluorescence of T65V EGFP was due to elimina-
tion of chromophore formation, not to a lack of the pres-
ence of mutant protein. (This observation was consistent
with the minimal background fluorescent signal also ob-
served in lysates of cells expressing T65V EGFP that
were subjected to quantitative analysis of the emission
spectra at 509 nm [excitation at 488 nm] [data not shown].)
Thus, thissystemprovidesaway tomonitor T misincorpo-
ration as a recovery of fluorescence.
Mistranslation Observed in Cells Expressing
Editing-Deficient ValRS
To examine the effects of the ValRS transgenes on Thr
misincorporation, the T65V EGFP biosensor was tran-
siently transfected into NIH/3T3 cells stably transfected
with inducible forms of either wild-type or T535P
ValRSD. After T65V transfection (allowing time for cellu-
lar recovery), ValRS transgenes were induced and
incubated for 12–18 hr to allow for build up of newly syn-
thesized proteins. In cells expressing wild-type ValRSD,
the minimal T65V EGFP fluorescence did not increase
(Figures 5A and 5B). In contrast, cells expressing
T535P ValRSD showed a clear gain in EFGP fluores-
cence (Figures 5A and 5C). This gain is consistent with
misincorporation of T at position 65 thereby restoring
the chromophore consensus sequence. The presence
of comparable amounts of T65V EGFP in cells harboring
either the gene for wild-type or T535P ValRSD was con-
firmed by probing with an antibody to GFP (anti-GFP IgG
Alexa Fluor 647). This analysis showed that the increase
in EGFP fluorescence resulted from the presence of the
editing-defective enzyme, not from an intrinsic differ-
ence in levels of EGFP.
To provide a more quantitative measure of fluores-
cence recovery due to misincorporation, cells were
lysed and samples were analyzed for fluorescence
emission. In addition, total EGFP fluorescence for each
cell sample was corrected for the amount of EGFP pro-
tein present. The fractional change in fluorescence was
then calibrated by comparing T65V EGFP fluorescence
for cells expressing the ValRSD transgenes versus those
in which ValRSD transgene expression had not been in-
duced. By using these two standards, a dynamic range
of fluorescence emission could be established. This
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(A) Schematic of EGFP biosensor. T / V
replacement at position 65 of EGFP is hy-
pothesized to alter its fluorescence profile,
allowing misincorporation of Thr at V65
(due to the presence of mischarged Thr-
tRNAVal generated by an editing-deficient
ValRS) to be visualized and measured as
the recovery of EGFP fluorescence.
(B and C) Transfection of NIH/3T3 cells with
(B) WT and (C) T65V EGFP shows a signifi-
cant decrease in T65V EGFP fluorescence.
Immunodetection with anti-GFP IgG Alexa
Fluor 647 illustrates equivalent distribution
of both WT and T65V EGFP.assay demonstrated anw16.7%6 1.5% gain in fluores-
cence in cells coexpressing T535P ValRSD and T65V
EGFP, a statistically significant gain (Figure 5A). In con-trast, cells expressing wild-type ValRSD did not exhibit
a significant quantitative increase in T65V EGFP fluores-
cence (1.75% 6 2.5%).Figure 5. Threonine Misincorporation De-
tected by EGFP Biosensor
(A–C) NIH/3T3 cells transfected with T65V
EGFP and induced to express either WT or
T535P ValRSD. (A) Fluorescence spectropho-
tometric analysis of cell lysates (emission at
507 nm; excitation at 488 nm) and visualiza-
tion by (B and C) fluorescence microscopy
demonstrate a gain in EGFP fluorescence
in cells expressing (C) T535P, but not (B)
WT, ValRSD. Emission values were corrected
for the amount of EGFP protein present in
each sample. The fractional change in fluo-
rescence represents a ratio of the T65V
EGFP fluorescence for cells expressing the
ValRSD transgenes versus uninduced cells.
Results are representative of means of three
independent experiments 6 SEM.
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Global Mistranslation
Release of mischarged tRNAs in a eukaryotic
cell generated by an editing-deficient amino-
acyl-tRNA synthetase and resulting in mis-
translation could impact a variety of areas
of cell physiology.In addition to the modified consensus sequence, the
EGFP protein contains 18 valines that, when substituted
with Thr, may alter the folding or fluorescent properties
of EGFP. Possibly, therefore, Val / Thr substitutions
at any of these positions could cause local denaturation
and exacerbate the loss of fluorescence. To investigate
this question, we attempted to ‘‘force’’ substitution of
Thr into the other valine codons of EGFP. This attempt
was made via raising the exogenous Thr concentration
10-fold. In this extreme circumstance, the fractional
gain in T65V fluorescence due to Thr insertion was
only slightly reduced (14.4% 6 0.4%, data not shown)
compared to the gain in fluorescence without increased
Thr (16.7% 6 1.5%). Thus, the effect of the insertion of
Thr at sites other than the target site appears to be
limited.
Discussion
In comparison to what has been observed in bacteria
and yeast, mammalian cells appear to be more sensitive
to mistranslation. In E. coli, cell viability is only affected
in cells in which the wild-type tRNA synthetase allele is
knocked out and growth is carried out in the presence
of a noncognate amino acid that can be mischarged
by the editing-deficient enzyme [14, 15]. InCandida albi-
cans, while introduction of ambiguity induces what ap-
pears to be a novel stress response (revealed in changes
in gene expression and cellular proteome content) that
is accompanied by a 50% reduction in growth rate, there
is no indication of cell death [56, 57]. In contrast, in mam-
malian cells, expression of an editing-deficient ValRS is
sufficient to cause dramatic changes in cell phenotype
and the initiation of an apoptotic response. Because
the mutant ValRS studied here acquired the ability to
cause amino acid misincorporation, the mutation can
be viewed as a gain-of-function mutation. As expected
for a gain-of-function mutation, it had a dominant-nega-
tive effect over the wild-type alleles.
Previous work showed that when E. coli ValRS bear-
ing the corresponding editing mutation (T222P) was
introduced into bacteria and grown in the presence of
a-Abu, global substitution (mistranslation) at Val codons
occurred at a level of up to 24% (as determined by aminoacid analysis). For an overexpressed individual protein,
the degree of misincorporation for a given peptide
ranged between 9.5% and 18% per Val codon (as deter-
mined by MALDI-mass spectrometry) [25]. In light of
this, it is particularly striking that the fractional gain of
16.7 % in T65V EGFP fluorescence, which was observed
in response to an editing-deficient murine ValRS in
mammalian cells, falls directly within the range of misin-
corporation rates observed under similar conditions in
bacteria. Although the fractional gain in fluorescence is
not considered to directly reflect the level of Thr misin-
corporation occurring at all Val codons, it has to relate
to the degree of Thr misincorporation occurring at
Val65 of EGFP. Therefore, this number may loosely re-
flect the degree of global misincorporation occurring
at Val codons when an editing-deficient ValRS is ex-
pressed in mammalian cells.
The observed sensitivity of mammalian cells to errors
in translation raises the broader question of the mecha-
nistic basis. Through many routes, cell and whole-or-
ganism physiology can be impacted by introduction of
global changes in primary protein sequence. These
routes include disruption of protein folding pathways,
creation of altered proteins with newly acquired inter-
actions, or induction of autoimmune-type responses
(Figure 6). During the folding process, proteins collapse
into their globular native states in a manner determined
by their primary amino acid sequence [58, 59]. Thus,
small changes in amino acid sequence have the poten-
tial to create unfolded polypeptides or misfolded protein
aggregates [60, 61]. The appearance of misfolded and/
or aggregated proteins in the endoplasmic reticulum
(ER) of eukaryotic cells activates a signaling cascade
(the unfolded protein response [UPR] [62, 63]) that,
when overwhelmed, can lead to cell death via apoptosis
[64, 65]. In this scenario, the formation of statistical pro-
teins leads to the initiation of the UPR and induction of
an apoptotic response. The accumulation of insoluble
protein aggregates is linked to many etiologically unre-
lated neurodegenerative disorders, pointing to what
could be a potential disease-related connection [66–70].
At the organism level, amino acid misincorporation
could plausibly trigger an autoimmune-like response.
By chemically altering tyrosine residues on the surface
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sulfanillic acid, Weigle and coworkers demonstrated
that, upon injection of the conjugated proteins into rab-
bits, antibodies formed over time and developed cross-
reactivity with their own native thyroglobulin [71, 72].
Prolonged exposure to these self-antibodies resulted
in thyroiditis. In principle, this phenomenon can occur
when altered proteins are generated by amino acid mis-
incorporation, that is, an immune response provoked in
response to altered proteins formed through transla-
tional errors could result in the targeting of native pro-
teins and the onset of an autoimmune-like condition.
Sequence alignments demonstrate a high level of
conservation in the editing domains of class I tRNA syn-
thetases. In particular, the region into which the T535P
mutation was introduced contains some of the most
highly conserved residues of the CP1 domain, with key
residues conserved in almost every ValRS, IleRS, and
LeuRS in organisms ranging from bacteria through
humans [32, 33, 73]. Although strict conservation of
this sequence throughout evolution shows that strong
selective pressure was exerted to retain the editing
function, the importance of hydrolytic editing in vivo
has only recently been demonstrated in bacteria. The
work presented here provides a powerful rationale for
this high level of conservation extending to mammals.
Significance
Components of the translation apparatus have been
associated with several pathologies and diseases.
We have investigated global effects of mistranslation
in mammalian cells in culture. AARSs prevent mis-
translation through specialized editing reactions that
clear any tRNAs that have been aminoacylated with in-
correct amino acids. Here, we mutationally disabled
the editing function of a murine tRNA synthetase that
normally has a potent editing activity. The mutant
enzyme is incapable of clearing mischarged tRNA
substrates, while, at the same time, it retains wild-
type aminoacylation activity. Stable NIH/3T3 mouse
fibroblast cell lines were engineered to inducibly
express the transgene encoding the mutant enzyme.
Prolonged induction of the editing-deficient tRNA
synthetase led to a pronounced dominant-negative
morphological phenotype. Phenotypic changes were
characterized by cell contraction,membrane blebbing,
and caspase-3 activation, consistent with an apopto-
tic-like response. By forcing the use of a noncanonical
amino acid that is misacylated and not cleared by
the editing-deficient enzyme, morphological effects
were exacerbated and activation of caspase-3 was in-
creased. To obtain a direct readout of mistranslation
in vivo, a modified EGFPmRNA was expressed, which
only produces fluorescent protein when mistransla-
tion occurs. This fluorescent sensor allowed detection
of mistranslation upon induction of the editing-
deficient tRNA synthetase. In contrast, no fluorescent
signal was seen upon induction of the wild-type tRNA
synthetase. These investigations show that mistrans-
lation can lead to mammalian cell pathologies and rai-
ses the possibility that it has a causal relationship with
genetic diseases.Experimental Procedures
Plasmid Construction
An EST ofw4 kb encoding a putative M. musculus ValRS was iden-
tified in an EST database (Invitrogen, clone 4971200) by searching
against the published sequence [35]. For expression and purification
from E. coli, the valS cDNA from clone 4917200 was subcloned into
pET28a (EMD Biosciences) by using SalI and NotI to attach an
N-terminal His tag upstream of the valS start codon (pLAN410).
The QuickChange Site-Directed Mutagenesis Kit (Stratagene) was
used to replace the ACC Thr535 codon with a CCC Pro codon
(pLAN441). For generation of transgenic cell lines, the coding
sequences for wild-type (WT) and T535P ValRSD were subcloned
into pGene/V5-His B (Invitrogen) by using HindIII and NotI sites
(pLAN438, pLAN443). For misincorporation studies, T65V EGFP
was constructed by using site-directed mutagenesis on pEGFP-
N1 (BD Clontech) to replace the ACC Thr65 codon with a GUG Val
codon.
Molecular Modeling
Sequence of M. musculus ValRS containing the editing domain
(residues M337–V1137) was submitted for fold recognition to the
3D-PSSM server (http://www.sbg.bio.ic.ac.uk/w3dpssm/). A model
was generated by using homology modeling based on the structure
of the T. thermophilus ValRS editing domain [34]. The model was
supported by an E-value of 0.0039, corresponding to confidence in
the prediction of >95%. Side chains were modeled in 3D-PSSM by
SCWRL.
Aminoacylation and Deacylation Assays
WT and T535P M. musculus ValRS were purified from E. coli (details
are available upon request), and concentrations were determined by
the Bradford assay (BioRad) and active site titration. Aminoacylation
assays were performed as previously described [22] at 37C in a
reaction mixture of 100 mM HEPES (pH 7.5), 20 mM KCl, 2 mM
ATP, 4 mM MgCl2, 2 mM DTT, 20 mM L-valine, 0.7 mM [
3H-L-valine],
100 mM calf liver tRNA (EMD Biosciences), and 25 nM WT or T535P
ValRS.
Mischarged [3H]-Thr-tRNAVal was generated by incubating E. coli
T222P ValRS (2 mM), purified E. coli tRNAVal (100 mM) (Sigma-
Aldrich), and [3H]-L-threonine (20 mM) for 30 min. Deacylation reac-
tions were performed at 25C in PVDF Multiscreen filter plates
(details upon request) with 25 nM enzyme and [3H]-Thr-tRNAVal
(11 mM) in 100 mM HEPES (pH7.5), 20 mM KCl, 10 mM MgCl2, and
2 mM DTT. Data points were averaged from duplicate experiments.
Cell Culture
Stably transfected cell lines (GeneSwitch NIH/3T3) were selected,
isolated, and maintained in DMEM plus 10% fetal bovine serum,
1% penicillin/streptomycin, 2 mM L-glutamine, 50 mg/ml hygromy-
cin, and 500 mg/ml zeomycin. Lipofectamine and Plus Reagent
were used for transfections. ValRSD expression was induced with
MFP (1 3 1028 M) and was detected by immunoblotting with anti-
V5-HRP mouse monoclonal antibody (cell culture reagents were
purchased from Invitrogen). Monoclonal anti-polyubiquitin anti-
body, clone FK1 (Biomol), was used to detect polyubiquitinated
proteins.
Caspase-3 Activation Assays
Assays measuring caspase-3 activation were performed with the
Caspase-3 Assay Kit (BD Pharmingen) according to manufacturer’s
instructions. Briefly, ValRSD transgenic cell lines were treated with
combinations of +/2MFP and a-Abu (100 mM) and were harvested
after 24 hr. For each sample, 6 3 106 cells were resuspended in
100 ml lysis buffer for the assay. AMC liberation was measured
with a FluoroMax-3 spectrofluorimeter (HORIBA Jobin Yvonn) (exci-
tation at 380 nm; emission at 420–460 nm). The fractional change in
fluorescence relative to uninduced cells was determined for each
sample. Data represent six independent experiments done in
duplicate.
Threonine Misincorporation Assays
WT and T535P ValRSDcell lines were grown tow60% confluency and
transfected with 2 mg pEGFP-N1 (EGFP) or pCMM149 (T65V EGFP)
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1099by using Effectene according to the manufacturer’s instructions
(QIAGEN). After recovery in growth media (1–2 hr), cells were prep-
ped for either fluorescence microscopy or quantitative analysis.
Fluorescence Microscopy
Cells were seeded onto fibronectin-coated glass coverslips and
treated with MFP for 12–18 hr. Cells were then fixed for 20 min in
2% formaldehyde/PBS, permeabilized in 0.2 % Triton X-100/PBS,
and rinsed with PBS. Cells were stained with anti-GFP IgG Alexa
Fluor 647 conjugate (Molecular Probes) and mounted in immuno-
fluoresence mounting medium (MP Biomedicals). Images were
acquired with a Bio-Rad (Zeiss) MRC1024 laser scanning confocal
microscope.
Fluorescence Spectrophotometry
Cells were lysed in M-PER Reagent (Pierce), and soluble fractions
were isolated. Samples were analyzed with a FluoroMax-3 spectro-
fluorimeter (HORIBA Jobin Yvonn) (excitation at 488 nm; emission at
507 nm). Units of EGFP per sample were determined by using
Amplex Red ELISA kit #1 (Molecular Probes) utilizing an anti-GFP
monoclonal antibody, JL-8 (Santa Cruz Biotechnology). HRP was
detected by using Amplex Red (excitation at 570 nm; emission at
585 nm), and relative concentrations of EGFP were determined by
using a standard curve based on purified EGFP protein standards.
Relative EGFP levels were verified by immunoblotting with the
same antibody set. Values generated were used to correct for the
amount of EGFP protein present in each sample.
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